Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year September 10, 2025 According to a new data update from REGENXBIO's pivotal phase 1/2/3 CAMPSIITE clinical trial (NCT03566043) evaluating clemidsogene lanparvovec (RGX-121), an investigational adeno-associated virus (AAV) vector-based gene therapy for mucopolysaccharidosis type 2 (MPSII, also known as Hunter syndrome), 13 patients treated in the pivotal phase have shown an 82% reduction in heparan sulfate (HS) D2S6 levels in the cerebrospinal fluid (CSF) through 1 year posttreatment
Spend TV Impressions National Impressions Local Impressions Check out Quicksilver Scientific's 30 second TV commercial, 'Train My Life' from the Vitamins & Supplements industry
Akondi, K
It contains tirzepatide , the same active ingredient found in the brand-name drugs Zepbound and Mounjaro
Aging (Albany NY) (2019) 11(2):53648
